Pediatric liver disease

Chatmanee Lertudomphonwanit; William F. Balistreri

doi:10.1016/B978-0-323-47874-8.00025-0

Pediatric liver disease

Chatmanee Lertudomphonwanit
, William F. Balistreri

Department of Pediatrics

Cincinnati Children’s Hospital Medical Center

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The causes and the management of liver disease in infants and young children differ greatly from those of adults. Early recognition of pathologic jaundice (conjugated hyperbilirubinemia) during infancy, exclusion of life-threatening conditions (hypoglycemia and liver failure) and diagnoses of treatable causes are critical steps in ensuring a successful outcome. Several inherited and metabolic disorders were discovered since 2005; in addition, novel specific treatment strategies have been proposed. However, for most affected patients, adequate nutritional support, monitoring for complications (portal hypertension and malignancy), and liver transplantation remain the mainstays of management.

Original language	English
Title of host publication	Handbook of Liver Disease
Publisher	Elsevier
Pages	335-350
Number of pages	16
ISBN (Electronic)	9780323478823
ISBN (Print)	9780323478748
DOIs	https://doi.org/10.1016/B978-0-323-47874-8.00025-0
Publication status	Published - 2018

Keywords

Familial intrahepatic cholestasis
Galactosemia
Hyperbilirubinemia
Inherited and metabolic liver disease
Mitochondrial hepatopathies
Neonatal cholestasis

Access to Document

10.1016/B978-0-323-47874-8.00025-0

Cite this

@inbook{5f66c135bd9043dbbbeb87f3f3a2a2a3,

title = "Pediatric liver disease",

abstract = "The causes and the management of liver disease in infants and young children differ greatly from those of adults. Early recognition of pathologic jaundice (conjugated hyperbilirubinemia) during infancy, exclusion of life-threatening conditions (hypoglycemia and liver failure) and diagnoses of treatable causes are critical steps in ensuring a successful outcome. Several inherited and metabolic disorders were discovered since 2005; in addition, novel specific treatment strategies have been proposed. However, for most affected patients, adequate nutritional support, monitoring for complications (portal hypertension and malignancy), and liver transplantation remain the mainstays of management.",

keywords = "Familial intrahepatic cholestasis, Galactosemia, Hyperbilirubinemia, Inherited and metabolic liver disease, Mitochondrial hepatopathies, Neonatal cholestasis",

author = "Chatmanee Lertudomphonwanit and Balistreri, \{William F.\}",

year = "2018",

doi = "10.1016/B978-0-323-47874-8.00025-0",

language = "English",

isbn = "9780323478748",

pages = "335--350",

booktitle = "Handbook of Liver Disease",

publisher = "Elsevier",

}

TY - CHAP

T1 - Pediatric liver disease

AU - Lertudomphonwanit, Chatmanee

AU - Balistreri, William F.

PY - 2018

Y1 - 2018

N2 - The causes and the management of liver disease in infants and young children differ greatly from those of adults. Early recognition of pathologic jaundice (conjugated hyperbilirubinemia) during infancy, exclusion of life-threatening conditions (hypoglycemia and liver failure) and diagnoses of treatable causes are critical steps in ensuring a successful outcome. Several inherited and metabolic disorders were discovered since 2005; in addition, novel specific treatment strategies have been proposed. However, for most affected patients, adequate nutritional support, monitoring for complications (portal hypertension and malignancy), and liver transplantation remain the mainstays of management.

AB - The causes and the management of liver disease in infants and young children differ greatly from those of adults. Early recognition of pathologic jaundice (conjugated hyperbilirubinemia) during infancy, exclusion of life-threatening conditions (hypoglycemia and liver failure) and diagnoses of treatable causes are critical steps in ensuring a successful outcome. Several inherited and metabolic disorders were discovered since 2005; in addition, novel specific treatment strategies have been proposed. However, for most affected patients, adequate nutritional support, monitoring for complications (portal hypertension and malignancy), and liver transplantation remain the mainstays of management.

KW - Familial intrahepatic cholestasis

KW - Galactosemia

KW - Hyperbilirubinemia

KW - Inherited and metabolic liver disease

KW - Mitochondrial hepatopathies

KW - Neonatal cholestasis

UR - https://www.scopus.com/pages/publications/85054237813

U2 - 10.1016/B978-0-323-47874-8.00025-0

DO - 10.1016/B978-0-323-47874-8.00025-0

M3 - Chapter

AN - SCOPUS:85054237813

SN - 9780323478748

SP - 335

EP - 350

BT - Handbook of Liver Disease

PB - Elsevier

ER -

Pediatric liver disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this